Fresenius Chief Financial Officer Michael Brosnan spoke about the upcoming financial costs of GranuFlo lawsuits facing the company at an earnings meeting. Brosnan confirmed that the company is preparing to face significant legal costs in dealing with GranuFlo and NaturaLyte, its dialysis acid concentrate products that were recalled after reports of significant injuries.